Cutaneous lupus skin lupus
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years. 2. Diagnosis of CLE is made by dermatologist based on clinical features and histopathological examination. 3. In case of a SLE, this diagnosis is made by a rheumatologist based on 2019 ACR/EULAR classification criteria for SLE. 4. Patients who have read, understood, and signed an informed consent document related to this specific study.
Exclusion criteria
Exclusion criteria: - Patients with any other dermatological of systemic disorder which would interfere with the results, at the discretion of the investigator. - Patients using topical corticosteroids and topical calcineurin inhibitors at biopsy site within one week prior to enrolment. - Patients who are or have been treated with specific B cell depleting/modifying therapies (Rituximab, Belimumab, Cyclophosphamide)in 12 months prior to inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective 1: Characterization of autoreactive B cells in CLE and SLE • Frequency and phenotype of autoreactive B cells in skin and circulation • Specificities of antibodies from cutaneous B cell supernatant in ELISA Objective 2: Determine the mechanisms for B cell tolerance breakthrough and plasma cell differentiation in the skin of CLE and SLE patients • Transcriptome of B cells in skin (scRNAseq) • B cell receptor repertoire of cutaneous B cells • Immune cell landscape of B cells in skin (imaging mass cytometry). | — |
Countries
Netherlands
Outcome results
None listed